Sarepta Therapeutics Stock Sinks After Company Says Patient Taking Its Drug Dies
Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.
Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday?
We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...
STAT6h
Cargo Therapeutics ends development efforts
Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...
MPR2h
Patient Dies Following Treatment With DMD Gene Therapy Elevidys
The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.
Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...
Sarepta's gene therapy under scrutiny after patient death
A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death linked to the treatment.
Sarepta Therapeutics (SRPT) Gets a Hold from Scotiabank
In a report released today, Louise Chen from Scotiabank maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Sarepta price target lowered to $99 from $124 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Sarepta (SRPT) to $99 from $124 and keeps a Hold rating on the shares after the company ...